Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Prof Jonathon Edwards to be IiME Rituximab trial advisor

Discussion in 'General ME/CFS News' started by Sasha, Jul 14, 2013.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    15,193
    Likes:
    36,917
    UK
    Jo Best, Bob, Esther12 and 5 others like this.
  2. Purple

    Purple Bundle of purpliness

    Messages:
    1,436
    Likes:
    2,489
    EXCELLENT NEWS!
    (yes, I did mean to shout this...)
     
    SOC, Dolphin, sproggle and 1 other person like this.
  3. user9876

    user9876 Senior Member

    Messages:
    2,227
    Likes:
    14,255
    sproggle, SOC, Esther12 and 2 others like this.
  4. Esther12

    Esther12 Senior Member

    Messages:
    8,106
    Likes:
    25,246
    Good news.

    Hopefully he might be able to advance work on finding a way of identifying those patients most likely to benefit. Linking the rituximab CFS work to others working in a similar area but outside of CFS seems like a really positive move.
     
    Sasha and Valentijn like this.
  5. Gemini

    Gemini Senior Member

    Messages:
    612
    Likes:
    1,057
    Esther,

    You're absolutely right!

    In RA they can identify non-responders to rituximab using an interferon [gene expression] signature:

    "The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients, " Arthritis Res Ther, April 2012

    http://www.ncbi.nlm.nih.gov/pubmed/22540992

    Let's hope the Professor is familiar with this groundbreaking work in another disease & can apply it to ME/CFS.
     
    Sasha and Valentijn like this.

See more popular forum discussions.

Share This Page